These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25163907)

  • 1. Cilengitide in glioblastoma: when did it fail?
    Chinot OL
    Lancet Oncol; 2014 Sep; 15(10):1044-5. PubMed ID: 25163907
    [No Abstract]   [Full Text] [Related]  

  • 2. Does cilengitide deserve another chance?
    Tucci M; Stucci S; Silvestris F
    Lancet Oncol; 2014 Dec; 15(13):e584-e585. PubMed ID: 25456376
    [No Abstract]   [Full Text] [Related]  

  • 3. Does cilengitide deserve another chance?-Authors' reply.
    Stupp R; Picard M; Weller M
    Lancet Oncol; 2014 Dec; 15(13):e585-e586. PubMed ID: 25456377
    [No Abstract]   [Full Text] [Related]  

  • 4. End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.
    Mason WP
    Neuro Oncol; 2015 May; 17(5):634-5. PubMed ID: 25681307
    [No Abstract]   [Full Text] [Related]  

  • 5. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
    Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
    Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
    Hegi ME; Stupp R
    Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690
    [No Abstract]   [Full Text] [Related]  

  • 8. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
    Khasraw M; Lee A; McCowatt S; Kerestes Z; Buyse ME; Back M; Kichenadasse G; Ackland S; Wheeler H
    J Neurooncol; 2016 May; 128(1):163-171. PubMed ID: 26935578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT methylation in glioblastoma: tale of the tail.
    Shah N; Schroeder B; Cobbs C
    Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuro-oncology: The many challenges of treating elderly glioblastoma patients.
    van den Bent MJ; Bromberg JE
    Nat Rev Neurol; 2015 Jul; 11(7):374-5. PubMed ID: 25986504
    [No Abstract]   [Full Text] [Related]  

  • 11. What role should cilengitide have in the treatment of glioblastoma?
    Chamberlain MC
    J Clin Oncol; 2010 Nov; 28(33):e695; author reply e696-7. PubMed ID: 20975074
    [No Abstract]   [Full Text] [Related]  

  • 12. Prime time for molecular marker diagnostics in neuro-oncology.
    Weller M; Stupp R
    Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
    [No Abstract]   [Full Text] [Related]  

  • 13. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide and MGMT forever?
    Weller M
    Neuro Oncol; 2010 Mar; 12(3):219-20. PubMed ID: 20167809
    [No Abstract]   [Full Text] [Related]  

  • 15. How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine.
    Chamberlain MC
    J Clin Oncol; 2011 Jun; 29(17):e517-8; author reply e519-20. PubMed ID: 21555685
    [No Abstract]   [Full Text] [Related]  

  • 16. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
    Parker NR; Hudson AL; Khong P; Parkinson JF; Dwight T; Ikin RJ; Zhu Y; Cheng ZJ; Vafaee F; Chen J; Wheeler HR; Howell VM
    Sci Rep; 2016 Mar; 6():22477. PubMed ID: 26940435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
    Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
    Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma in the elderly.
    Chamberlain MC
    Cancer Treat Res; 2015; 163():159-70. PubMed ID: 25468231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
    Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
    J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.